Get started
Author

Imran Tanvir

Observed names: I Tanvir, I. Tanvir, Tanvir, Imran
OpenAlex ID: A5044494381
Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice
2021 · Minying Royston, Adrian Kielhorn, et al. · Neurology and Therapy · 47
PDF
Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder
2021 · Dean M. Wingerchuk, Ina Zhang, et al. · Neurology and Therapy · 37
PDF
Clinical burden of relapses in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: A single center cohort analysis
2021 · Robert Kadish, Stacey L. Clardy, et al. · Journal of Neuroimmunology · 8
A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”
2022 · Dean M. Wingerchuk, Ina Zhang, et al. · Neurology and Therapy · 2
PDF
Neuromyelitis Optica Spectrum Disorder (NMOSD): Epidemiology, Treatments, and Outcomes in a Single Center (4629)
2020 · Robert Kadish, Tavan Parker, et al. · Neurology · 1
Indirect Comparison Analysis of FDA-Approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder (P15-1.007)
2022 · Dean Wingerchuk, Sean Pittock, et al. · Neurology
POSA8 Indirect Comparison Analysis of United States Food and Drug Administration-Approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder
2022 · D Wingerchuk, SJ Pittock, et al. · Value in Health
Pnd52 Economic Burden of an Acute Relapse Due to Neuromyelitis Optica Spectrum Disorder (nmosd)
2020 · A. Kielhorn, M. Royston, et al. · Value in Health
PDF
Pnd32 Acute and Chronic Costs of Neuromyelitis Optica Spectrum Disorder (nmosd) Management: All-cause and Relapse-related Charge Data in a Single Center
2020 · T.H. Parker, R. Kadish, et al. · Value in Health
Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study (1299)
2020 · Kazuo Fujihara, Achim Berthele, et al. · Neurology
Benefit of eculizumab for a broad range of patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from prevent
2020 · K Fujihara, Achim Berthele, et al. · mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich)
Works count: 13
Citation count: 95
H-index: 3
I10-index: 2
Year
Topic
Type